Literature DB >> 29048104

Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis.

Joan How1, Kathryn M Trinkaus2, Stephen T Oh1.   

Abstract

Entities:  

Keywords:  essential thrombocythaemia; myeloproliferative neoplasm; polycythaemia vera; primary myelofibrosis; splanchnic vein thrombosis

Mesh：

Substances：

Year:  2017        PMID： 29048104     DOI： 10.1111/bjh.14958

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Authors:  Brady L Stein; Karlyn Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.

Authors:  Alexandre Guy; Johanne Poisson; Chloe James
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

3.  Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.

Authors:  Pierre-Edouard Debureaux; Bruno Cassinat; Juliette Soret-Dulphy; Barbara Mora; Emmanuelle Verger; Nabih Maslah; Aurelie Plessier; Pierre-Emmanuel Rautou; Isabelle Ollivier-Hourman; Victor De Ledinghen; Odile Goria; Christophe Bureau; Claudia Siracusa; Dominique Valla; Stephane Giraudier; Francesco Passamonti; Jean-Jacques Kiladjian
Journal:  Blood Adv       Date:  2020-08-11

4.  Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?

Authors:  Stephen E Langabeer
Journal:  J Transl Int Med       Date:  2018-06-26

Review 5.  The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Suzanne McPherson; Ken Mills; Mary Frances McMullin
Journal:  J Transl Med       Date:  2018-12-17       Impact factor: 5.531

6.  Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series.

Authors:  Graeme Greenfield; Mary Frances McMullin
Journal:  Thromb J       Date:  2018-12-19

7.  Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania.

Authors:  Luise Grunwald; Christina Grosse-Thie; Sina Sender; Gudrun Knuebel; Saskia Krohn; Catrin Roolf; Christian Junghanss; Larissa Henze; Hugo Murua Escobar
Journal:  Biomark Res       Date:  2020-12-14

8.  JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.

Authors:  Paola Guglielmelli; Giuseppe G Loscocco; Valerio De Stefano; Alessandro M Vannucchi; Carmela Mannarelli; Elena Rossi; Francesco Mannelli; Francesco Ramundo; Giacomo Coltro; Silvia Betti; Chiara Maccari; Sara Ceglie; Patrizia Chiusolo; Chiara Paoli; Tiziano Barbui; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2021-12-11       Impact factor: 11.037

Review 9.  Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Leukemia       Date:  2021-09-03       Impact factor: 11.528

Review 10.  Molecular pathogenesis of the myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Mary Frances McMullin; Ken Mills
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.